Moreover, activating PIK3CA mutations are observed in ER negative breast cancer as well [4], and mTOR inhibition, combined with trastuzumab and paclitaxel, prolonged progression-free survival significantly among patients with hormone receptor negative, HER2 positive breast cancer [5]. Here, ERBB2 is linked to breast carcinoma.